Evidence map›Paper›PMID 39174604›Full record

ArticleScientific reports2024

Incidence and prognosis of taxane-induced macular edema: a retrospective study from the Japan Clinical REtina Study Group (J-CREST).

Hiroki Tsujinaka, Sho Imoto, Tetsuo Ueda, Makiko Wakuta, Yutaka Yamada, Takaaki Sugisawa, Fumiko Murao, Takao Hirano, Shigeo Yoshida, Kumiko Kato and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hiroki TsujinakaDepartment of Ophthalmology, Nara Medical University, Kashihara, 6348521, Japan.
Sho ImotoDepartment of Ophthalmology, Nara Medical University, Kashihara, 6348521, Japan.
Tetsuo UedaDepartment of Ophthalmology, Nara Medical University, Kashihara, 6348521, Japan. tueda@naramed-u.ac.jp.
Makiko WakutaDepartment of Ophthalmology, Yamaguchi University, Ube, 7558505, Japan.
Yutaka YamadaDepartment of Ophthalmology, Fukui University, Eiheiji, 9101193, Japan.
Takaaki SugisawaDepartment of Ophthalmology, Hyogo Medical University, Nishinomiya, 6638501, Japan.
Fumiko MuraoDepartment of Ophthalmology, Tokushima University, Tokushima, 7708503, Japan.
Takao HiranoDepartment of Ophthalmology, Shinshu University, Matsumoto, 3908621, Japan.
Shigeo YoshidaDepartment of Ophthalmology, Kurume University, Kurume, 8300011, Japan.
Kumiko KatoDepartment of Ophthalmology, Mie University Graduate School of Medicine, Tsu, 5148507, Japan.
Mariko SasakiDepartment of Ophthalmology, Tachikawa Hospital, Tachikawa, 1908531, Japan.
Riko MatsumotoDepartment of Ophthalmology, Shiga University of Medical Science, Otsu, 5202192, Japan.
Gaku IshigookaDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, Takatsuki, 5698686, Japan.
Nahoko OgataDepartment of Ophthalmology, Nara Medical University, Kashihara, 6348521, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macular edema is a known side effect of taxane-based anticancer drugs. We retrospectively investigated data from 11 centers between January 2016 and December 2021. Among 14,260 patients, 30 (0.21%) developed macular edema; from these, the number of cases associated with nab-paclitaxel was 16 (0.43%), significantly higher than the number of cases associated with paclitaxel or docetaxel (P < 0.01). Visual acuity (VA) and retinal choroidal change were examined in 27 patients, with a follow-up of at least 3 months. The patients' mean age was 67.2 years; 14 (51.3%) were male and four (14.8%) had unilateral onset. The mean interval between anticancer drug initiation and the first ophthalmology visit was 290.1 days. Among the 20 patients who discontinued anticancer drugs, VA and edema significantly improved 2 months after discontinuation (LogMAR VA: 0.50 vs. 0.28, central retinal thickness: 472.7 µm vs. 282.5 µm, both P < 0.01). No significant changes were observed in the central choroidal thickness. A correlation was found between duration of taxane treatment and VA immediately before discontinuation of anticancer drugs (β = 0.00050; 95% confidence interval: 0.00036-0.00097; P < 0.05). Although taxane-induced macular edema is reversible, slower anticancer drug discontinuation worsened VA, highlighting the need for regular ophthalmologic evaluation during treatments.

Indexed as

Macular EdemaTaxoidsVisual AcuityAgedAged, 80 and overAntineoplastic AgentsBridged-Ring CompoundsDocetaxelFemaleHumansIncidenceJapanMaleMiddle AgedPaclitaxelPrognosisAntineoplastic AgentsBridged-Ring CompoundsDocetaxelPaclitaxeltaxaneTaxoidsIncidenceMacular edemaTaxane-based anticancer drugs

Identifiers

PMID39174604
PMCPMC11341814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.